We serve Chemical Name:2-(trifluoromethyl)pyrimidine-4,5,6-triamine CAS:2927-11-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(trifluoromethyl)pyrimidine-4,5,6-triamine
CAS.NO:2927-11-9
Synonyms:4,5,6-Triamino-2-trifluormethyl-pyrimidin;2-trifluoromethyl-pyrimidine-4,5,6-triamine;2,4,6-Triamino-2-trifluormethyl-pyrimidin
Molecular Formula:C5H6F3N5
Molecular Weight:193.13000
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:288.7ºC at 760 mmHg
Density:1.661g/cm3
Index of Refraction:1.606
PSA:103.84000
Exact Mass:193.05800
LogP:1.98560
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4,5,6-Triamino-2-trifluormethyl-pyrimidin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,4,6-Triamino-2-trifluormethyl-pyrimidin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4,6-Triamino-2-trifluormethyl-pyrimidin Use and application,2,4,6-Triamino-2-trifluormethyl-pyrimidin technical grade,usp/ep/jp grade.
Related News: The mode of cooperation between domestic API companies and large international companies can lower the export threshold. 2-(trifluoromethyl)pyrimidine-4,5,6-triamine manufacturer ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. 2-(trifluoromethyl)pyrimidine-4,5,6-triamine supplier China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases. 2-(trifluoromethyl)pyrimidine-4,5,6-triamine vendor The mode of cooperation between domestic API companies and large international companies can lower the export threshold. 2-(trifluoromethyl)pyrimidine-4,5,6-triamine factory ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.
